title: Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance.
abstract: BACKGROUND
  Cachexia is a multiorganic syndrome associated with cancer, characterized by body weight loss, muscle and adipose tissue wasting and inflammation.
  
  
  METHODS
  The aim of this investigation was to examine the effect of the soluble receptor antagonist of myostatin (sActRIIB) in cachectic tumor-bearing animals analyzing changes in muscle proteolysis and in quality of life.
  
  
  RESULTS
  Administration of sActRIIB resulted in an improvement in body and muscle weights. Administration of the soluble receptor antagonist of myostatin also resulted in an improvement in the muscle force.
  
  
  CONCLUSIONS
  These results suggest that blocking myostatin pathway could be a promising therapeutic strategy for the treatment of cancer cachexia.
authors.forename: Sílvia
authors.initials: S
authors.lastname: Busquets
authors.forename: Míriam
authors.initials: M
authors.lastname: Toledo
authors.forename: Marcel
authors.initials: M
authors.lastname: Orpí
authors.forename: David
authors.initials: D
authors.lastname: Massa
authors.forename: Maria
authors.initials: M
authors.lastname: Porta
authors.forename: Eva
authors.initials: E
authors.lastname: Capdevila
authors.forename: Núria
authors.initials: N
authors.lastname: Padilla
authors.forename: Valentina
authors.initials: V
authors.lastname: Frailis
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: López-Soriano
authors.forename: H Q
authors.initials: HQ
authors.lastname: Han
authors.forename: Josep M
authors.initials: JM
authors.lastname: Argilés